Solitary sites of metastatic disease in non-small cell lung cancer

Current Treatment Options in Oncology

Volumn 4, Issue 1, 2003, Pages 65-79

  Schuchert, Matthew J ^a   Luketich, James D ^b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b NONE

Author keywords

Brain Metastasis; Docetaxel; Gemcitabine; Main Side Effect; Vinorelbine

Indexed keywords

ANTINEOPLASTIC AGENT;

ADRENAL TUMOR; BRAIN TUMOR; CLINICAL TRIAL; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METASTASIS; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; RADIATION DOSE; REVIEW; SURVIVAL RATE;

ADRENAL GLAND NEOPLASMS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; PROGNOSIS; RADIOTHERAPY DOSAGE; SURVIVAL RATE;

EID: 0037711178     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-003-0033-8     Document Type: Article

References (50)

1. Greenlee RT, Murray T, Bolden S, et al.: Cancer statistics? CA Cancer J Clin 2000, 50:7–33.
2. Schottenfield D: Etiology and epidemiology of lung cancer. In Lung Cancer Principles and Practice. Edited by Pass HI, Mitchell JB, Johnson DH, et al. Philadelphia: Lippincott Williams & Wilkins; 1994:367–388.
3. Quint LE, Tummala S, Brisson LJ, et al.: Distribution of distant metastases from newly-diagnosed non-small cell lung cancer? Ann Thorac Surg 1996, 62:246–250. DOI: 10.1016/0003-4975(96)00220-2
4. Shepherd FA: Treatment of advanced non-small cell lung cancer? Semin Oncol 1994, 21(Suppl 7):7–18.
5. Albain KS, Crowley JJ, LeBlanc M, et al.: Survival determinants in extensive-stage non-small cell lung cancer: the Southwest Oncology Group experience? J Clin Oncol 1991, 9:1618–1626.
6. Dockery DW, Trichopoulos D: Risk of lung cancer from environmental exposures to tobacco smoke? Cancer Causes Control 1997, 8:333–345. DOI: 10.1023/A:1018401120233
7. Williams MD, Sandler AB: The epidemiology of lung cancer? Cancer Treat Res 2001, 105:31–52.
8. Bonney GE: Interactions of genes, environment and lifestyle in lung cancer development? J Natl Cancer Inst 1990, 82:1236–1237. DOI: 10.1093/jnci/82.15.1236
9. Parker MS, Leveno DM, Campbell TJ, et al.: AIDSrelated bronchogenic carcinoma: fact or fiction? Chest 1998, 113:154–161.
10. Johnson DH: Evolution of cisplatin-based chemotherapy in non-small cell lung cancer: a historical perspective and the Eastern Cooperative Oncology Group experience? Chest 2000, 117(Suppl 1):133S-137S. An excellent review of the development of platinum-based therapy as the leading front-line regimen in the treatment of advanced and metastatic NSCLC. DOI: 10.1378/chest.117.4_suppl_1.133S
11. Rapp E, Pater JL, Willan A, et al.: Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer: report of a Canadian multicenter randomized trial? J Clin Oncol 1988, 6:633–641.
12. Ranson M, Davidson N, Nicholson M, et al.: Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small cell lung cancer? J Natl Cancer Inst 2000, 92:1074–1080. DOI: 10.1093/jnci/92.13.1074
13. Roszkowski K, Pluzanska A, Krzakowski M, et al.: A multicenter, randomized, phase III study of docetaxel plus best supportive care vs best supportive care in chemotherapy-naïve patients with metastatic or unresectable localized non-small cell lung cancer (NSCLC)? Lung Cancer 2000, 37(3):145–157. DOI: 10.1016/S0169-5002(00)00094-5
14. Effects of vinrelbine on quality of life and survival of elderly patients with advance non-small cell lung cancer: the Elderly Lung Cancer Vinrelbine Italian Study Group. J Natl Cancer Inst 1999, 91:66–72.
15. Anderson H, Hopwood P, Stephens RJ, et al.: Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer: a randomized trial with quality of care as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer? Br J Cancer 2000, 83:447–453. DOI: 10.1054/bjoc.2000.1307
16. Bonomi P, Kim KM, Fairclough D, et al.: Comparison of survival and quality of life in advanced non-small cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin vs etoposide with cisplatin: results of an Eastern Cooperative Group trial? J Clin Oncol 2000, 18:623–631.
17. Wozniak AJ, Crowley JJ, Balcerzak SP, et al.: Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advance non-small cell lung cancer: a Southwest Oncology Group study? J Clin Oncol 1998, 16:2459–2465.
18. Sandler AB, Memunaitis J, Denham C, et al.: Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally-advanced or metastatic non-small cell lung cancer? J Clin Oncol 2000, 18:122–130.
19. Gandara D, Vokes E, Green M, et al.: Activity of docetaxel in platinum-treated non-small cell lung cancer results of a phase II multicenter trial? J Clin Oncol 2000, 18:131–135.
20. Schiller JH, Harrington D, Belani CP, et al.: Comparison of four chemotherapy regimens for advanced nonsmall cell lung cancer? N Engl J Med 2002, 346:92–98. A systematic review of the principal regimens in use as frontline therapy for locally advanced and metastatic NSCLC. DOI: 10.1056/NEJMoa011954
21. Khuri FR, Herbst RS, Fossella FV: Emerging therapies in non-small cell lung cancer? Ann Oncol 2001, 12:739–744. DOI: 10.1023/A:1011197500223
22. Gandara D, Edelman M, Lau D: Emerging role of docetaxel (taxotere) in advanced non-small cell lung cancer? Semin Oncol 1999, 26:3–7.
23. Belani CP, Einzig A, Bonomi P, et al.: Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small cell lung cancer? Ann Oncol 2000, 11:673–678. DOI: 10.1023/A:1008342116536
24. Kakolyris S, Kouroussis C, Souglakos J, et al.: Cisplatin and irinotecan (CPT-11) as second-line treatment in patients with advanced non-small cell lung cancer? Lung Cancer 2001, 34(Suppl 4):S71-S76. DOI: 10.1016/S0169-5002(01)00384-1
25. Clegg A, Scott DA, Hewitson P, et al.: Clinical and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small cell lung cancer: a systematic review? Thorax 2002, 57:20–28. DOI: 10.1136/thorax.57.1.20
26. Sause WT: The role of radiotherapy in non-small cell lung cancer? Chest 1999, 116(Suppl 6):504s-508s. DOI: 10.1378/chest.116.suppl_3.504S
27. Ueki K, Matsutani M, Nakamura O, et al.: Comparison of whole brain irradiation therapy and locally-limited radiation therapy in the treatment of solitary brain metastases from non-small cell lung cancer? Neurol Med Chir 1996, 36:364–369. DOI: 10.2176/nmc.36.364
28. Kim YS, Kondziolka D, Flickinger JC, et al.: Stereotactic radiosurgery for patients with non-small cell lung carcinoma metastatic to the brain? Cancer 1997, 80:2075–2083. An informative retrospective study of 77 patients with solitary metastases from NSCLC. As the largest series dedicated to NSCLC metastases, it highlights the factors that were found to impact on survival of patients: extent of systemic disease, presence of a neurologic deficit, size of the intracranial tumor, initial imaging appearance of intratumoral necrosis, and initial resection of the primary lung tumor. DOI: 10.1002/(SICI)1097-0142(19971201)80:11<2075::AID-CNCR6>3.0.CO;2-W
29. Alexander E, Moriarty TM, Davis RB, et al.: Stereotactic radiosurgery for the definitive, non-invasive treatment of brain metastases? J Natl Cancer Inst 1995, 87:34–40. DOI: 10.1093/jnci/87.1.34
30. Li B, Yu J, Suntharalingam M, et al.: Comparison of three treatment options for single brain metastasis for lung cancer? Int J Cancer 2000, 90:37–45. DOI: 10.1002/(SICI)1097-0215(20000220)90:1<37::AID-IJC5>3.0.CO;2-7
31. Coy P, Schaafsma J, Schofield JA: The cost-effectiveness and cost-utility of high-dose palliative radiotherapy for advanced non-small cell lung cancer? Int J Radiat Oncol Biol Phys 2000, 48:1025–1033. DOI: 10.1016/S0360-3016(00)00713-6
32. Schwartz M: Stereotactic radiosurgery: comparing different technologies? CMAJ 1998, 158:625–628.
33. Patchell RA, Tibbs PA, Walsh JW, et al.: A randomized trial of surgery in the treatment of single metastases to the brain? N Engl J Med 1990, 322:494–500. This is the only randomized study evaluating the role of surgical resection in the treatment of solitary metastases to the brain from NSCLC. DOI: 10.1056/NEJM199002223220802
34. Burt M, Wronski M, Arbit E, et al.: Resection of brain metastasis from non-small cell lung carcinoma: results of therapy. Memorial Sloan-Kettering Cancer Center thoracic surgical staff? J Thorac Cardiovasc Surg 1992, 103:399–411.
35. Mussi A, Pistolesi M, Lucchi M, et al.: Resection of single brain metastasis in non-small cell lung cancer: prognostic factors? J Thorac Cardiovasc Surg 1996, 112:146–153. DOI: 10.1016/S0022-5223(96)70190-3
36. Billing PS, Miller DL, Allen MS, et al.: Surgical treatment of primary lung cancer with synchronous brain metastases? J Thorac Cardiovasc Surg 2001, 122:548–553. DOI: 10.1067/mtc.2001.116201
37. Macchiarini P, Buonaguidi R, Hardin M, et al.: Results and prognostic factors of surgery in the management of non-small cell lung cancer with solitary brain metastasis? Cancer 1991, 70:2021–2023.
38. Luketich JD, Burt ME: Does resection of adrenal metastases from non-small cell lung cancer improve survival? Ann Thorac Surg 1996, 62:1614–1616. DOI: 10.1016/S0003-4975(96)00611-X
39. Abdel-Raheem MM, Potti A, Becker WA, et al.: Late adrenal metastasis in operable non-small cell lung carcinoma? Am J Clin Oncol 2002, 25:81–83. DOI: 10.1097/00000421-200202000-00017
40. Thompson GB, Grant CS, van Heerden JA, et al.: Laparoscopic versus open posterior adrenalectomy: a case-control study of 100 patients? Surgery 1997, 122:1132–1136. DOI: 10.1016/S0039-6060(97)90218-X
41. Ambrogi V, Tonini G, Mineo TC: Prolonged survival after extracranial metastasectomy from synchronous resectable lung cancer? Ann Surg Oncol 2001, 8:663–666. DOI: 10.1007/s10434-001-0663-7
42. Porte H, Joëlle S, Benoit G, et al.: Resection of adrenal metastases from non-small cell lung cancer? Ann Thorac Surg 2001, 71:981–985. DOI: 10.1016/S0003-4975(00)02509-1
43. Beitler AL, Urschel J, Velagapudi S, et al.: Surgical management of adrenal metastases from lung cancer? J Surg Oncol 1998, 69:54–57. DOI: 10.1002/(SICI)1096-9098(199809)69:1<54::AID-JSO11>3.0.CO;2-N
44. Santini M, Vicidomini G, DiMarino P, et al.: Solitary muscle metastasis from lung carcinoma? J Cardiovasc Surg 2001, 42:701–702.
45. McKeown PP, Conant P, Auerbach LE: Squamous cell carcinoma of the lung: an unusual metastasis to pectoralis muscle? Ann Thorac Surg 1996, 61:1525–1526. DOI: 10.1016/0003-4975(95)01177-3
46. Luketich JD, Martini N, Ginsberg R, et al.: Successful treatment of solitary extracranial metastases from non-small cell lung cancer? Ann Thorac Surg 1995, 60:1609–1611. This study provides the largest series of patients undergoing aggressive surgical resection of extracranial solitary metastases from NSCLC, demonstrating substantial long-term survival rates (86%) in appropriately selected patients. DOI: 10.1016/0003-4975(95)00760-1
47. Rowinsky EK, Windle JJ, Von Hoff DD: Ras protein farnesyltransferase: a strategic target for anti-cancer therapeutic development? J Clin Oncol 1999, 17:3631–3652.
48. Sirotnak FM, Miller VA, Scher HI, et al.: Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by co-administration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase? Clin Cancer Res 2000, 6:4885–4892.
49. Recchia F, Sica G, De Filippis S, et al.: Cisplatin, vindesine, mitomycin-C and 13-cis retinoic acid in the treatment of advanced non-small cell lung cancer: a phase II pilot study? Anticancer Res 2000, 20:1985–1990.
50. DeVore RF, Fehrenbacher L, Herbst RS, et al.: A randomized phase II trial comparing rhuMab VEGF (recombinant human monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/ paclitaxel alone in patients with stage IIIB/IV NSCLC [abstract]? Proc Am Soc Clin Oncol 2000, 19:485.